#ATTRCM
LightNews LightNews
jaccjournals.bsky.social
Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://bit.ly/4gLv5DG

#HFSA2025 #JACC #CardioSky
September 28, 2025 at 2:22 PM
asnc.bsky.social
"We're entering an era where patients should expect not to die 𝘧𝘳𝘰𝘮 cardiac #amyloidosis but rather 𝘸𝘪𝘵𝘩 it.” — Dr. Michelle Kittleson

Early diagnosis + treatment are changing outcomes in #ATTRCM. Age-expected longevity may be w/in reach.
Read🔗 bit.ly/4qBtZid

Sponsored by Alnylam Pharmaceuticals
November 4, 2025 at 3:44 PM
jaccjournals.bsky.social
New ACC Concise Clinical Guidance updates best practices for diagnosing and managing transthyretin amyloid #cardiomyopathy, highlighting disease-modifying and HF therapies plus future directions. https://bit.ly/49nYX7m

#JACC #Amyloidosis #ATTRCM #HeartFailure #CardioSky
October 31, 2025 at 2:05 PM
drrossupton.bsky.social
🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀

📖 Read the full article: doi.org/10.1093/eurh...

#Cardiology #PrecisionMedicine #Amyloidosis #ATTRCM @escardio.bsky.social
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
Abstract. Development of specific therapies addressing the underlying diseases’ mechanisms constitutes the basis of precision medicine. Transthyretin cardi
doi.org
March 18, 2025 at 10:36 AM
rarediseaseadvisor.bsky.social
#LiverTransplantation and treatment with disease-modifying therapies significantly improve survival in patients with hereditary variant transthyretin amyloidosis, which can lead to cardiomyopathy (#ATTRCM) and polyneuropathy (#ATTRPN). @jinternmed.bsky.social

Read more: https://bit.ly/48j6jZt
Platelets Play a Key Role in MG Pathogenesis
A new study supports the notion that activated platelets play a key role in the pathogenesis of myasthenia gravis (MG).
bit.ly
October 7, 2025 at 7:11 PM
rnaianalyst.bsky.social
#$bbio impressive 1028 #ATTRCM Attruby scripts written since Nov22,2024 launch. $536M 2024 net loss.

www.cnbc.com/2025/02/16/t...

#$alny #$ions #$ntla
Trump administration cuts reach FDA employees in food safety, medical devices and tobacco products
Recently hired employees at the Food and Drug Administration who review the safety of food ingredients, medical devices and other products were fired.
www.cnbc.com
February 20, 2025 at 1:08 PM
accintouch.bsky.social
🆕 Concise Clinical Guidance addresses evaluation & management of #ATTRCM & provides updated strategies & best practices, taking into account expanding disease modifying therapies, #heartfailure therapies & potential future opportunities.

More: 🔗 https://bit.ly/4qBQvYd #JACC #Amyloidosis #CardioSky
October 31, 2025 at 7:10 PM
jaccjournals.bsky.social
New in #JACC: A cross-trial analysis of 3 cardiac amyloidosis #ATTRCM trials reveals time-dependent effects of modern disease-modifying therapies on mortality.

Get the details: www.jacc.org/doi/10.1016/...

#ATTRMeeting2025 #ATTR2025 #Amyloidosis #CardioSky
September 25, 2025 at 1:25 PM
rarediseaseadvisor.bsky.social
Happy HallowThankMas! 🎃 🦃 🎄

ATTR-CM Contributor Faye Adams is celebrating the season a little differently this year — by creating moments whenever she can, not just when the calendar says it’s time.

✨Read more here: https://bit.ly/47ZFb10

#RareDisease #ATTRCM #RareVoices #MedSky
November 26, 2025 at 3:47 PM
rarediseaseadvisor.bsky.social
Accurate differentiation between light-chain (AL) amyloidosis and #ATTRCM is critical for effective patient management, as misclassification can delay life-saving therapies for #ALAmyloidosis or result in unnecessary interventions for ATTR-CM.

Learn more: https://bit.ly/4q8BrAH
AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges
This article explores key differences and diagnostic challenges between light-chain amyloidosis and ATTR-CM.
bit.ly
January 6, 2026 at 8:54 PM
rarediseaseadvisor.bsky.social
The extracellular volume derived from cardiac #MRI is highly accurate in identifying patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM) who have negative technetium-99m-pyrophosphate (Tc-PyP) scans. @jaccjournals.bsky.social

Read more: https://bit.ly/47SHof0

#MedSky #RareSky
Cardiac MRI May Lead to Early Diagnosis in ATTR-CM Care
The extracellular volume derived from cardiac MRI highly accurate in identifying patients with ATTR-CM with negative Tc-PyP scans.
bit.ly
September 24, 2025 at 4:56 PM
rarediseaseadvisor.bsky.social
#AHA25: Researchers developed a machine learning model that outperforms the Mayo #ATTRCM score in differentiating the disease from other #CardiacConditions. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/441KpXt

#RareDisease #MedTech #Cardiology
AI Tool Successfully Distinguishes ATTR-CM From Other Diseases
A new machine learning model performed better than the Mayo ATTR-CM score in discerning ATTR-CM from other heart conditions.
bit.ly
November 8, 2025 at 8:15 PM
rarediseaseadvisor.bsky.social
#AHA25: While #Transthyretin (TTR) stabilizers reduce the risk of cardiovascular events in patients with #ATTRCM in a real-world setting, data on #TTR gene silencers is more limited. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/485pntu
Real-World Analysis Supports Efficacy of ATTR-CM Therapies
A retrospective analysis of patient health records found that transthyretin stabilizers show clinical benefit in adults with ATTR-CM.
bit.ly
November 8, 2025 at 7:48 PM
rarediseaseadvisor.bsky.social
Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), whether or not they were treated with #Tafamidis. Study in Clinical Research in Cardiology.

Read more: https://bit.ly/4pun9d5
Tafamidis May Slow the Progression of ATTR-CM
Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with ATTR-CM, per a recent study.
bit.ly
November 25, 2025 at 4:44 PM
rcatanho.bsky.social
Disfunción auricular izquierda es común en pacientes con amiloidosis trantiretina con cardiomiopatía y representa peor pronóstico, y vutisiran atenúa el empeoramiento en la tensión auricular izquierda a los 30m #vutisiran #ATTRCM jamanetwork.com/journals/jam...
Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy
This secondary analysis of the HELIOS-B randomized clinical trial evaluates the prognostic significance of left atrial structure and function among patients with transthyretin amyloidosis with cardiom...
jamanetwork.com
September 2, 2026 at 9:29 AM
jaccjournals.bsky.social
Vutrisiran benefits were consistent across baseline tafamidis use, with reduced effect size observed in those on stabilizers. Findings support further study of combination therapy. https://bit.ly/45R2LuY

#ESCCongress #JACC #ATTRCM #CardioSky
August 30, 2026 at 12:20 PM
gmj-georgia.bsky.social
Long-term data from Nature Medicine's NI006-101 trial show cliramitug—a monoclonal antibody against misfolded transthyretin—sustains clinical benefit…

#ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonalantibody

#ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonala…
Monoclonal antibody cliramitug sustains benefit in cardiac amyloidosis
Long-term data from Nature Medicine's NI006-101 trial show cliramitug—a monoclonal antibody against misfolded transthyretin—sustains clinical benefit… #ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonalantibody
news.gmj.ge
August 21, 2026 at 1:30 PM
jamacardiology.com
Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months. ja.ma/4f3mNIq
JAMA Cardiology article titled, "Long-Term Durability of Acoramidis Efficacy..." includes Kaplan-Meier curves for Time to All-Cause Mortality ([ACM]@number) and Cardiovascular-Related Mortality ([CVM]@number) through Month 54, comparing Continuous Acoramidis vs. Placebo.
May 23, 2026 at 11:00 AM
jamacardiology.com
Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months.

#ACC26 @accintouch.bsky.social

ja.ma/4bGqr9d
JAMA Cardiology article presents Kaplan-Meier curves for time to all-cause mortality (ACM) and cardiovascular-related mortality (CVM) through month 54. Graphs compare continuous acoramidis to placebo, showing survival probability over time with stratified Cox regression analysis.
March 30, 2026 at 7:00 PM
med-iqcardiology.bsky.social
18/New insights in ATTR-CM—Patients on tafamidis showed greater functional stability at 12 months, and that stability strongly predicted survival. Early preservation of function matters. #ATTRCM
Infographic summarizing tafamidis post hoc findings in ATTR-CM: higher functional stability at 12 months, functional stability strongly predictive of survival, 73% lower mortality in stable patients, and lower CV hospitalization rates vs placebo. Second slide: Bullet summary of tafamidis impact on mortality and hospitalization, showing lower mortality in stable vs progressing patients, reduced CV hospitalizations even with functional decline, and benefit across functional trajectories.
June 30, 2026 at 7:38 PM
med-iqcardiology.bsky.social
11/11
How do patients with #ATTRCM die?

New insights from Kevin Alexander, MD and Masri Ahmad, MD #ATTRibuteCM at #HeartFailure2025

#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM
med-iqcardiology.bsky.social
9/11
More from #ATTRibuteCM

In variant #ATTRCM, acoramidis led to a reduction in the composite of ACM/CVH, ACM and CVH.

These clinical benefits were accompanied by halting in the rise in NT-proBNP levels, suggesting underlying disease-modifying effects.

#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM
med-iqcardiology.bsky.social
8/11
New data from #ATTRibuteCM presented at #HeartFailure2025

Intriguing analysis by Kevin Alexander, MD. High-affinity TTR stabilizer acoramidis potentially associated with lower risks of AF/AFL events in #ATTRCM

#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM
med-iqcardiology.bsky.social
3/11
Remarkable back-to-back! #HeartFailure2025 #LBCT by
Marianna Fontana.

Nex-z CRISPR gene editing based therapy in #ATTRCM. Main paper in @nejm.org www.nejm.org/doi/full/10....

New data by #ATTR type with consistent and durable TTR lowering

#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM
med-iqcardiology.bsky.social
1/11
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:

#LBCT by Marianna Fontana

#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM

#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM